Advanced GIST | AG0102 GIST / EORTC 62005
Phase III randomised, multi-centre, international trial to determine the relation between dose and clinical activity of STI—571 in patients with unresectable or metastatic malignant gastrointestinal stromal tumors expressing the c—kit receptor tyrosine kinase (CD117).
Schema
.gif)
Summary
Gastro—intestinal stromal tumours (GIST) are rare and highly resistant to standard chemotherapy and radiation. A new chemotherapy tablet called STI—571 (Glivec®) has produced dramatic responses in people with this kind of cancer. This trial is comparing higher and lower doses of STI—571 to see which works best. Trials of STI—571 in other cancers are being planned around the world.
